AstraZeneca and its subsidiary Alexion struck a deal to acquire gene therapy biotech LogicBio for 667% premium. LogicBio brings its GeneRide technology and genomic medicine experience to Alexion. (Endpoints News)
The U.S. Supreme Court denied Biogen’s bid to reinstate a patent on its multiple sclerosis drug Tecfidera. Biogen previously sued Mylan Pharmaceuticals over the company’s proposed generic MS drug, arguing it infringed Biogen patents. (Reuters)
Pfizer completed its acquisition of Biohaven Pharmaceuticals. The deal, which was first announced in May, closed for $11.6 billion. (Seeking Alpha)
A new model indicated that Type 1 diabetes cases worldwide could double by 2040. The estimates counter some myths about the disease, which was once called juvenile diabetes because its onset often occurs during childhood. (The Washington Post)
Mental health researchers are exploring whether smartphones and other wearable devices like FitBits can predict suicide risk and lead to earlier interventions. Experts hope the devices can help monitor people who are at risk for suicide but are at home and not in a hospital. (The New York Times)
